Mylan Communications With CMS To Get Outside Review Under EpiPen Settlement
Corporate integrity agreement requires Mylan to have an independent body review its drug classifications and US best price determinations; settlement resolves claims Mylan misclassified EpiPen to underpay rebates. Sanofi acted as whistleblower in case.
You may also be interested in...
After “four years of vigorous litigation,” Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan “to monopolize the market” for the EpiPen autoinjector device.
House Ways & Means Committee clears legislation requiring manufacturers to justify 10% WAC increase in one year and 25% increase over three years, and to report number of free product samples.
Two-and-a-half years after receiving a complete response letter, Teva's ANDA clears FDA; agency issued three guidances for development of generic epinephrine auto-injectors.